Clinical Trial Update: To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety, tolerability, and efficacy of bedaquiline (TMC207) as part of an individualized MDR-TB treatment regimen in sputum smear-po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Tuberculosis

Drugs mentioned

• bedaquiline (bedaquiline)

Snippet

Sponsor: Janssen Infectious Diseases BVBA | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2013-05-16